About Herbert Smith Freehills
As one of the world’s leading law firms, we advise many of the largest and most ambitious organisations across all major regions of the globe. With over 5,000 people, including 3,100 lawyers and over 2,000 business services professionals, operating from our global network of offices across Asia Pacific, Europe, the Middle East and North America, Herbert Smith Freehills is at the heart of the new global business landscape providing premium quality, full-service legal advice.
We recognise that the success of our business and our clients relies on the skills, knowledge and ideas of all our people. Our environment is one in which high performance is expected, in return, we will provide you with rewards and opportunities tailored to your personal and professional goals.
The Opportunity
Our team
Our Greater China capital markets team is equipped to provide full legal services in both debt and equity capital markets with a strong track record of advising issuers and underwriters on public offerings and private placements of debt and equity across a wide range of industry sectors.
Our ECM practice have advised many high profile and "first of its kind" IPOs including unprecedented spin-off listings, A to H listing, and simultaneous A and H dual listings. Our extensive experience dealing with complex legal structures and technical issues helps our clients to get the deal through. We also have a US securities capability which provides support on US securities laws and liability issues. The combination of our technical excellence, reliability and customer centric approach allows us to provide an all rounded high quality service experience to our clients.
We are one of the leaders in the healthcare and biotech field particularly for advising sponsors. Since the introduction of the Listing Rules' Chapter 18A biotech/pharma changes we have advised a number of 18A healthcare listings including listings by Antengene (06996.HK), Shanghai Junshi Biosciences (01877.HK), TOT BIOPHARM (01875.HK), SinoMab Bioscience Limited (03681.HK), Peijia Medical (09996.HK), Carsgen Therapeutics (02171.HK), Brii Biosciences (02137.HK), HeartCare (06609.HK), Acotec (06669.HK), Abbisko (02256.HK) and Bioheart (02185.HK).



Team
Corporate
Full time
Location
Beijing, Shanghai
Contract type



Diversity & Inclusion
We are committed to attracting people from all backgrounds and creating a respectful and inclusive culture where everyone thrives. We see this as essential to our success, including our ability to innovate and achieve sustained high performance. This is a key part of our Values—Human, Bold, and Outstanding.



The firm's representative offices in China remain registered as Herbert Smith Freehills LLP Beijing Representative Office (UK) and Herbert Smith Freehills LLP Shanghai Representative Office (UK) with the PRC Ministry of Justice. We are in the process of updating our name in China which is pending regulatory approval.
